Read More

Tonix Pharmaceuticals Announces Research Collaboration With Columbia University To Study Recombinant Trefoil Factor 2 Based Therapy For Gastric And Colorectal Cancers

TNX-1700 is Under Development as Monotherapy and in Combination with Anti-PD1 Checkpoint Inhibitor Therapy in Animal Models of Two Challenging Cancers   In Mouse Models, rTFF2 Detoxifies the Tumor Microenvironment,TNX-1700 is Under Development as Monotherapy and in Combination with Anti-PD1 Checkpoint Inhibitor Therapy in Animal Models of Two Challenging Cancers

TNXP